Euro-Sante :: Euro-Health

Archives for Innovation and Growth

One of the real issues facing EU members, particularly those that are having trouble paying their healthcare bills from suppliers, is the way that medicines are priced. The issue of drug pricing is likely to become even more important internationally as the UK pricing system will move to ‘value-based pricing’ in a year when the… » read more

Posted by EuroSante

A recently released report from the European Observatory on Health Systems and Policies has produced a retrospective on what over 40 European countries did in response to the financial crisis, triggered in 2007. The report “Health policy responses to the financial crisis in Europe” (by Mladovsky, Srivastava, Cylus, Karanikolos, Evetovits, Thomson, McKee) is here. The… » read more

Posted by EuroSante

Euractiv has reported on Commissioner Dalli’s comments that the Euro-zone crisis should not turn into a public health crisis. He added: “difficult times can indeed provide an incentive to think creatively and push forward in-depth reforms and contain costs, while building modern, responsive, and sustainable health systems fit for the future.” I agree, yet despair.… » read more

Posted by EuroSante

In this Age of Austerity, good ideas risk being lost. The dynamics of funding of innovations has always been full of risk. But as various debt-laden governments try to balance bloated public balance sheets, should we worry about where the ‘next big thing’ will come from? Yes, if you believe that governments can find and… » read more

Posted by EuroSante

  Does the proposed amending directive on providing medicines information to the general public (sometimes thought of as advertising) actually enhance patients’ rights? Will it lead to good regulation? The document in question can be found here. I’ll grant that a lot of people have been involved in this, so there must be some consensus,… » read more

Posted by EuroSante